Dr. Reddy's Laboratories Entered into a License and Distribution Agreement with CardiaCare to Commercialize Digital Neuromodulation Wearable for Non-invasive Atrial Fibrillation
Shots:
- CardiaCare to receive up front & royalty while Dr. Reddy's Laboratories will be responsible for the clinical studies to secure regulatory clearance in India & will lead the commercialization & distribution
- The device consists of a closed-loop approach, integrating therapy, monitoring optimizes & personalizes care to AF patients using AI-based ECG analysis algorithms. In the clinical studies, the novel therapeutic approach showed a reduction in AF precursors, and overall disease burden & has both acute & cumulative effects
- The agreement advances CardiaCare's evidence-generation & commercialization activity. The device is safe & drug-free and used for at-home treatment to increase AF treatment efficacy & decreases costs
Ref: PRNewswire | Image: uniQure
Related news :-
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
